-Patricia S Steeg Researcher Activity Profile

Research Author Detailed Information 

Patricia S Steeg Publication Rate By Year

Patricia S Steeg has published 8 paper(s) in 2007, 4 paper(s) in 2008, for a total of 12 research publications in total.

Patricia S Ps Steeg Author Information

LAST NAME: steeg

FIRST NAME: Patricia S

INITIALS: ps

AFFILIATION:

Papers

Patricia S Steeg's Publication Record

1. The biology of metastasis to a sanctuary site. Year Published: 2007
Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
2. Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Year Published: 2007
Center for Cancer Research, National Cancer Institute, Frederick, Maryland. varticol@mail.nih.gov
3. Cancer: micromanagement of metastasis. Year Published: 2007
4. Quantitative assessment of the p53-Mdm2 feedback loop using protein lysate microarrays. Year Published: 2007
Molecular Therapeutics Program, National Cancer Institute, NIH, Bethesda, Maryland, USA.
5. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Year Published: 2007
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA.
6. Cancer: micromanagement of metastasis. Year Published: 2007
7. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Year Published: 2007
Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. horakc@mail.nih.gov
8. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Year Published: 2007
Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. horakc@mail.nih.gov
9. Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility. Year Published: 2008
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
10. In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide. Year Published: 2008
Authors' Affiliations: Radiation Oncology Branch, Molecular Radiation Therapeutics Branch, and Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland.
11. Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility. Year Published: 2008
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
12. Metastasis: a therapeutic target for cancer. Year Published: 2008
Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. steegp@mail.nih.gov